𝔖 Bobbio Scriptorium

✦ LIBER ✦

69 Conformationally restricted analogs of a new class of potent non-nucleoside reverse transcriptase inhibitors: R. Noreen1, P. Engelhardt1, J. Kangametsa1, C. Sahlberg1, L. Vrang1, J. M. Morin, Jr.2, R. J. Ternansky2, and H. Zhang1. 1Medivir AB, Huddinge, Sweden; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

Book ID: 118393138
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 42 KB
Volume: 20
Category: Article
ISSN: 0166-3542
DOI: 10.1016/0166-3542(93)90447-q

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

70 Conformational studies on a new class

70 Conformational studies on a new class of potent non-nucleoside reverse transcriptase inhibitors: P. Lind1, R. Noreen1, and J. B. Deeter2. 1Medivir AB, Huddinge, Sweden; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 42 KB

71 SAR studies optimizing HIV-1 inhibiti

71 SAR studies optimizing HIV-1 inhibiting activities of LY73497, a new series of non-nucleoside inhibitors of reverse transcriptase: P. Engelhardt1, M. Hoberg1, J. Kangametsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, L. Vrang1, H. Zhang1, B. Oberg1, N. G. Johansson1, F. W. Bell2, A. S. Cantrell2, J. A. Palkowitz2, S. R. Jaskunas2, C. L. Jordan2, M. D. Kinnick2, J. M. Morin, Jr.2, C. A. Parrish2, P. Pranc2, R. J. Ternansky2, R. T. Vasileff2, and S. J. West2. 1Medivir AB, Huddinge, Sweden; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 62 KB

43 The discovery and general SAR studies

43 The discovery and general SAR studies of a novel class of potent non-nucleoside reverse transcriptase inhibitors: R. J. Ternansky1, J. M. Morin, Jr.1, C. Lopez1, C. J. Paget, Jr.1, F. W. Bell1, A. S. Cantrell1, S. R. Jaskunas1, C. L. Jordan1, M. D. Kinnick1, J. A. Palkowitz1, C. A. Parrish1, P. Pranc1, R. T. Vasileff1, S. J. West1, M. Hogberg2, P. Lind2, R. Noreen2, C. Sahlberg2, X.-X. Zhou2, L. Vrang2, C. Rydergard2, C. Ahgren2, B. Oberg2, and N. G. Johansson2. 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; 2Medivir AB, Huddinge, Sweden

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 50 KB

45 Comparative efficacy of HIV inhibitor

45 Comparative efficacy of HIV inhibitors on cells infected with cell free HIV or cocultivated with HIV-infected cells: L. Vrang1, C. Rydergard1, C. Ahgren1, P. Engelhardt1, M. Hogberg1, J. Kangasmetsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, N. G. Johansson1, C. Lopez2, J. M. Morin, Jr.2, R. J. Ternansky2, F. W. Bell2, C. L. Jordan2, M. D. Kinnick2, J. A. Palkowitz2, C. A. Parrish2, P. Pranc2, R. T. Vasileff2, S. J. West2, and B. Oberg1. 1Medivir AB, Huddinge, Sweden; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 83 KB

60 Inhibition of wild type and mutant HI

60 Inhibition of wild type and mutant HIV reverse transcriptases by a new class of non-nucleoside reverse transcriptase inhibitors: H. Zhang1, L. Vrang1, K. Backro2, T. Unge2, P. Engelhardt1, M. Hogberg2, J. Kangasmetsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, N. G. Johansson1, A. S. Cantrell3, S. R. Jaskunas3, J. M. Morin, Jr.3, R. J. Ternansky3, F. W. Bell3, C. L. Jordan3, M. D. Kinnick3, J. A. Palkowitz3, C. A. Parrish3, P. Pranc3, R. T. Vasileff3, S. J. West3, and B. Oberg1. 1Medivir AB, Huddinge, Sweden; 2Department of Molecular Biology, BMC, Uppsala, Sweden; 3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 57 KB

61 Comparative rates of in vitro resista

61 Comparative rates of in vitro resistance development of HIV-1 to new non-nucleoside analog RT inhibitors: L. Vrang1, C. Rydergard1, C. Ahgren1, P. Engelhardt1, M. Hogberg1, N. G. Johansson1, J. Kangasmetsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, A. Karlsson2, C. Lopez3, J. M. Morin, Jr.3, R. J. Ternansky3, F. W. Bell3, C. L. Jordan3, M. D. Kinnick3, J. A. Palkowitz3, C. A. Parrish3, P. Pranc3, R. T. Vasileff3, S. J. West3, and B. Oberg1. 1Medivir AB, Huddinge, Sweden; 2Department of Biochemistry, Stockholm, Sweden; 3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 81 KB